255 related articles for article (PubMed ID: 34165361)
1. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R
Mult Scler; 2021 Oct; 27(12):1960-1964. PubMed ID: 34165361
[TBL] [Abstract][Full Text] [Related]
2. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A
Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971
[TBL] [Abstract][Full Text] [Related]
6. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
Aerts S; Khan H; Severijns D; Popescu V; Peeters LM; Van Wijmeersch B
Mult Scler Relat Disord; 2023 Jul; 75():104735. PubMed ID: 37192586
[TBL] [Abstract][Full Text] [Related]
8. Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis.
Gummi R; Walsh RD; Ahmad B
Mult Scler Relat Disord; 2021 Feb; 48():102661. PubMed ID: 33321344
[TBL] [Abstract][Full Text] [Related]
9. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; Verdun di Cantogno E
Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898
[TBL] [Abstract][Full Text] [Related]
11. The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
Butzkueven H; Moore N; Aydemir A; Sõnajalg J; Bezemer I; Korhonen P; Sabidó M;
Curr Med Res Opin; 2022 Jul; 38(7):1167-1176. PubMed ID: 35357268
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
Zanetta C; Rocca MA; Meani A; Martinelli V; Ferrè L; Moiola L; Filippi M
J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
[TBL] [Abstract][Full Text] [Related]
13. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
14. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
[TBL] [Abstract][Full Text] [Related]
15. Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal.
Santos M; Sequeira J; Abreu P; Guerreiro R; Santos M; Ferreira J; Brum M; Ladeira F; Leitão L; Dias R; Sá MJ; Salgado V; Capela C; de Sá J
Clin Neuropharmacol; 2023 May-Jun 01; 46(3):105-111. PubMed ID: 37191564
[TBL] [Abstract][Full Text] [Related]
16. Cladribine (Mavenclad) for multiple sclerosis.
Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
[No Abstract] [Full Text] [Related]
17. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
Adamec I; Brecl Jakob G; Rajda C; Drulović J; Radulović L; Bašić Kes V; Lazibat I; Rimac J; Cindrić I; Gržinčić T; Abičić A; Barun B; Gabelić T; Gomezelj S; Mesaroš Š; Pekmezović T; Klivényi P; Krbot Skorić M; Habek M
J Neuroimmunol; 2023 Sep; 382():578164. PubMed ID: 37536052
[TBL] [Abstract][Full Text] [Related]
18. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
Rauma I; Viitala M; Kuusisto H; Atula S; Sipilä JOT; Ryytty M; Soilu-Hänninen M; Järvinen E
Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129
[TBL] [Abstract][Full Text] [Related]
19. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.
Hermann R; Litwin JS; Friberg LE; Dangond F; Munafo A
Br J Clin Pharmacol; 2019 Jul; 85(7):1484-1494. PubMed ID: 30883839
[TBL] [Abstract][Full Text] [Related]
20. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.
Moser T; Ziemssen T; Sellner J
Wien Med Wochenschr; 2022 Nov; 172(15-16):365-372. PubMed ID: 35451662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
